PIK3CA and cancer: Among these mutations, E545K (c.1633G>A) and E542K (c.1624G>A) were found in 20 (7.0%) and 11 (3.8%) cancers, respectively; H1047R (c.3140A>G) was found in 2 cancers and was associated with an increased response to PI3K/AKT/mTOR signaling pathway inhibitors in a previous clinical trial [8].